We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Renal Cell Carcinoma

Journal Scan / Research · November 02, 2020

Development of a Novel Prognostication Model for Patients With Metastatic RCC Receiving First-Line Molecularly Targeted Therapy

Urologic Oncology: Seminars & Original Investigations

 

Additional Info

Urologic Oncology: Seminars & Original Investigations
Development of Novel ACN (Albumin, C-Reactive Protein and Neutrophil-to-Lymphocyte Ratio) Prognostication Model for Patients With Metastatic Renal Cell Carcinoma Receiving First-Line Molecular-Targeted Therapy
Urol. Oncol 2020 Sep 18;[EPub Ahead of Print], K Tamura, R Ando, K Takahara, T Ito, K Kanao, T Yasui, R Shiroki, H Miyake

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading